主要终点-话题@MedSci

#主要终点#

97篇内容 | 2619人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1996964, encodeId=86951996964a0, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Spectrum的Poziotinib未能达到II期肺癌研究的主要终点, objectType=article, longId=185424, objectId=83501854242a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83501854242a, replyNumber=0, likeNumber=73, createdTime=2020-09-09, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83501854242a, moduleTitle=Spectrum的Poziotinib未能达到II期肺癌研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83501854242a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996951, encodeId=f5c41996951fc, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, objectType=article, longId=176549, objectId=9a1f1e654908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1f1e654908, replyNumber=0, likeNumber=83, createdTime=2019-10-24, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1f1e654908, moduleTitle=斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a1f1e654908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996972, encodeId=1f8a19969e24d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, objectType=article, longId=192235, objectId=15911922351b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15911922351b, replyNumber=0, likeNumber=58, createdTime=2021-03-02, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15911922351b, moduleTitle=百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15911922351b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996962, encodeId=520f199696212, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点, objectType=article, longId=183997, objectId=f31218399ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31218399ec7, replyNumber=0, likeNumber=98, createdTime=2019-12-26, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31218399ec7, moduleTitle=ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31218399ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996954, encodeId=1aa419969541d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点, objectType=article, longId=178211, objectId=25671e8211a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25671e8211a0, replyNumber=0, likeNumber=78, createdTime=2020-06-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25671e8211a0, moduleTitle=抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25671e8211a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996959, encodeId=bc0d1996959fb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, objectType=article, longId=181451, objectId=7dae1814517d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dae1814517d, replyNumber=0, likeNumber=62, createdTime=2020-06-11, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dae1814517d, moduleTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dae1814517d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996952, encodeId=c6901996952ec, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Rivipansel治疗镰状细胞病的III期试验：未达到主要终点, objectType=article, longId=176941, objectId=47371e6941f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47371e6941f2, replyNumber=0, likeNumber=67, createdTime=2020-03-27, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47371e6941f2, moduleTitle=Rivipansel治疗镰状细胞病的III期试验：未达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47371e6941f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996968, encodeId=4785199696809, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=肺动脉高压（PAH）治疗的Sotatercept达到II期研究的主要终点, objectType=article, longId=186904, objectId=685a1869048d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=685a1869048d, replyNumber=0, likeNumber=0, createdTime=2020-08-27, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=685a1869048d, moduleTitle=肺动脉高压（PAH）治疗的Sotatercept达到II期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=685a1869048d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996961, encodeId=ee7919969610a, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, objectType=article, longId=183554, objectId=f33d18355468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f33d18355468, replyNumber=0, likeNumber=101, createdTime=2020-05-01, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f33d18355468, moduleTitle=2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f33d18355468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996953, encodeId=2985199695312, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, objectType=article, longId=178209, objectId=6ad01e8209da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad01e8209da, replyNumber=0, likeNumber=0, createdTime=2020-02-24, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad01e8209da, moduleTitle=JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad01e8209da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996966, encodeId=8ce11996966f6, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=62, createdTime=2020-02-22, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996956, encodeId=03bf1996956a5, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=AR-105治疗呼吸机相关性肺炎（VAP）的中期研究未能达到主要终点, objectType=article, longId=178801, objectId=7ef71e88018b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ef71e88018b, replyNumber=0, likeNumber=69, createdTime=2019-09-22, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ef71e88018b, moduleTitle=AR-105治疗呼吸机相关性肺炎（VAP）的中期研究未能达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ef71e88018b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996950, encodeId=307e1996950bb, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, objectType=article, longId=176189, objectId=bfbc1e6189e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbc1e6189e0, replyNumber=0, likeNumber=81, createdTime=2020-03-14, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbc1e6189e0, moduleTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfbc1e6189e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996946, encodeId=107619969464a, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, objectType=article, longId=161873, objectId=c2ee1618e324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ee1618e324, replyNumber=0, likeNumber=60, createdTime=2020-01-25, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ee1618e324, moduleTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ee1618e324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996948, encodeId=8c8819969481c, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=JAMA：很大样本房颤消融和药物治疗随机对照研究：主要终点无差异，但住院率降低，生活质量提高, objectType=article, longId=163322, objectId=bc90163322d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc90163322d3, replyNumber=0, likeNumber=59, createdTime=2019-04-23, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc90163322d3, moduleTitle=JAMA：很大样本房颤消融和药物治疗随机对照研究：主要终点无差异，但住院率降低，生活质量提高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc90163322d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996945, encodeId=5e25199694539, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点, objectType=article, longId=161868, objectId=3a6b1618681b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a6b1618681b, replyNumber=0, likeNumber=81, createdTime=2019-11-17, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a6b1618681b, moduleTitle=Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a6b1618681b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996947, encodeId=9f24199694e5d, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, objectType=article, longId=162242, objectId=fef6162242d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fef6162242d9, replyNumber=0, likeNumber=69, createdTime=2020-02-14, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fef6162242d9, moduleTitle=Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fef6162242d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996942, encodeId=bd1f19969420c, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=利格列汀心血管结局试验CAROLINA达到主要终点, objectType=article, longId=160146, objectId=6a171601469f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a171601469f, replyNumber=0, likeNumber=81, createdTime=2019-10-11, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a171601469f, moduleTitle=利格列汀心血管结局试验CAROLINA达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a171601469f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996949, encodeId=d3b1199694954, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, objectType=article, longId=165652, objectId=69a116565258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a116565258, replyNumber=0, likeNumber=77, createdTime=2019-12-02, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a116565258, moduleTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a116565258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1996944, encodeId=bcad199694465, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, objectTitle=RNAi疗法givosiran治疗急性肝性卟啉症的晚期研究达到主要终点, objectType=article, longId=161863, objectId=36da16186308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36da16186308, replyNumber=0, likeNumber=73, createdTime=2020-02-17, rootId=0, userName=zhangj7108, userId=7387164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36da16186308, moduleTitle=RNAi疗法givosiran治疗急性肝性卟啉症的晚期研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36da16186308)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

主要终点

2020-05-29

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Spectrum的Poziotinib未能达到II期肺癌研究的主要终点

2020-09-09

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

斑秃靶向治疗：口服ATI-501治疗斑秃的II期临床试验达到其主要终点

2019-10-24

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

百济神州宣布，抗PD-1单抗替雷利珠单抗联合化疗用于非鳞状非小细胞肺癌患者，3期试验达到无进展生存的主要终点

2021-03-02

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

ChemoCentryx的Avacopan补体5a受体抑制剂治疗血管炎的III期试验达到了主要终点

2019-12-26

仁医06 (审核中...)

前往app查看评论内容

#主要终点#

抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点

2020-06-15

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点

2020-06-11

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Rivipansel治疗镰状细胞病的III期试验：未达到主要终点

2020-03-27

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

肺动脉高压（PAH）治疗的Sotatercept达到II期研究的主要终点

2020-08-27

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

2019 ESMO亚洲大会：国产曲妥珠单抗仿制药HLX02治疗乳腺癌在全球III期试验达到了主要终点

2020-05-01

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

JAK抑制剂Olumiant联合治疗特应性皮炎的III期试验达到主要终点

2020-02-24

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-02-22

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

AR-105治疗呼吸机相关性肺炎（VAP）的中期研究未能达到主要终点

2019-09-22

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点

2020-03-14

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点

2020-01-25

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

JAMA：很大样本房颤消融和药物治疗随机对照研究：主要终点无差异，但住院率降低，生活质量提高

2019-04-23

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点

2019-11-17

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

Eli Lilly的Cyramza作为转移性非小细胞肺癌的一线治疗达到了3期临床试验的主要终点

2020-02-14

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

利格列汀心血管结局试验CAROLINA达到主要终点

2019-10-11

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点

2019-12-02

zhangj7108 (审核中...)

前往app查看评论内容

#主要终点#

RNAi疗法givosiran治疗急性肝性卟啉症的晚期研究达到主要终点

2020-02-17

科室
- - 订阅+
  - 更多科室
工具
服务